LearnGlossaryMarketStocksSuperinvestorsSign in

ARWR

Arrowhead Pharmaceuticals, Inc.

Healthcare · $9.2B market cap

Verdict

We can't put a fair value on ARWR right now. The financial data we receive for it contains an obvious error (its cash-flow profit is more than 10× its reported profit for the same year). We'll value it once the data is corrected.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth0.7% a year✗
Sales growth39.9% a year✓
Free cash flow growth-0.4% a year✗
Return on invested capital-27.8%✗

Follow ARWR

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

2 of the investors we track hold ARWR. In Q2 2026, 2 opened a position. Who we track

Howard Marks

Oaktree Capital Management · as of Q2 2026

$11.0M

9,146,000 shares

Polen Capital Management

Polen Capital Management · as of Q2 2026

$539K

6,612 shares

Moves in Q2 2026

New position: Polen Capital Management, Howard Marks

About Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works